

**Anti-CCL5 / RANTES Reference Antibody (NI-0701)**  
**Recombinant Antibody**  
**Catalog # APR10276****Specification****Anti-CCL5 / RANTES Reference Antibody (NI-0701) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P13501</a>
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	145 KDa

**Anti-CCL5 / RANTES Reference Antibody (NI-0701) - Additional Information****Target/Specificity**  
CCL5 / RANTES**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in 100mM Pro-Ac, 20mM Arg, pH5.0, without preservative. This antibody is purified through a protein A column.**Anti-CCL5 / RANTES Reference Antibody (NI-0701) - Protein Information****Name** CCL5**Synonyms** D17S136E, SCYA5**Function**  
Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) (PubMed:<a href="http://www.uniprot.org/citations/1380064" target="\_blank">1380064</a>, PubMed:<a href="http://www.uniprot.org/citations/15923218" target="\_blank">15923218</a>, PubMed:<a href="http://www.uniprot.org/citations/15923218" target="\_blank">15923218</a>).

href="http://www.uniprot.org/citations/16791620" target="\_blank">16791620</a>, PubMed:<a href="http://www.uniprot.org/citations/8525373" target="\_blank">8525373</a>, PubMed:<a href="http://www.uniprot.org/citations/9516414" target="\_blank">9516414</a>). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:<a href="http://www.uniprot.org/citations/23979485" target="\_blank">23979485</a>).

#### Cellular Location

Secreted.

#### Tissue Location


Expressed in the follicular fluid (at protein level). T-cell and macrophage specific.

### Anti-CCL5 / RANTES Reference Antibody (NI-0701) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-CCL5 / RANTES Reference Antibody (NI-0701) - Images



Anti-CCL5 / RANTES Reference Antibody (NI-0701) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CCL5 / RANTES Reference Antibody (NI-0701) is more than 98.94% ,determined by SEC-HPLC.